Shares of Erasca, Inc. (NASDAQ:ERAS - Get Free Report) were down 4.1% during mid-day trading on Wednesday . The company traded as low as $16.15 and last traded at $16.08. 768,033 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 6,012,599 shares. The stock had previously closed at $16.76.
Wall Street Analysts Forecast Growth
ERAS has been the subject of a number of research analyst reports. Mizuho lowered their target price on Erasca from $28.00 to $26.00 and set an "outperform" rating for the company in a research note on Tuesday, May 12th. HSBC set a $20.00 price target on Erasca in a research note on Tuesday, July 14th. Guggenheim raised their price objective on Erasca from $20.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. Wolfe Research set a $16.00 target price on shares of Erasca in a report on Thursday, June 4th. Finally, HC Wainwright upped their target price on shares of Erasca from $18.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $22.09.
Check Out Our Latest Analysis on ERAS
Erasca Stock Performance
The firm has a 50-day moving average price of $18.29 and a 200-day moving average price of $15.64. The stock has a market cap of $5.53 billion, a PE ratio of -16.67 and a beta of 0.64.
Erasca (NASDAQ:ERAS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). As a group, sell-side analysts anticipate that Erasca, Inc. will post -0.49 EPS for the current fiscal year.
Institutional Investors Weigh In On Erasca
Several institutional investors and hedge funds have recently made changes to their positions in ERAS. Nykredit A S purchased a new stake in Erasca during the 2nd quarter valued at $29,000. Allworth Financial LP purchased a new position in shares of Erasca in the second quarter worth $34,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Erasca by 77.8% during the first quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company's stock valued at $69,000 after purchasing an additional 1,859 shares in the last quarter. KBC Group NV purchased a new stake in shares of Erasca during the first quarter valued at $81,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Erasca during the second quarter valued at $106,000. Institutional investors own 67.78% of the company's stock.
About Erasca
(
Get Free Report)
Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca's approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.
Erasca's pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Erasca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.
While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
